Dr. Mark Hyman Longevity: What Clinicians Should Tell Patients

Who Is Dr. Mark Hyman and Why Are Patients Asking?

Dr. Mark Hyman is a practicing family physician, founder of the Cleveland Clinic Center for Functional Medicine, and author of more than a dozen books, including Young Forever (2023). He reaches millions of followers through the podcast "The Doctor's Farmacy" and frequent appearances on mainstream media.

Patients bring his name into clinical visits because he speaks with both medical credentials and personal testimonial authority. That combination creates a specific challenge: his claims are more technically sophisticated than typical wellness influencer content, yet many of the interventions he discusses sit outside current standard-of-care guidelines. Clinicians need to engage with the specifics, not dismiss them wholesale.

What Hyman Says About His Own Protocol

In a 2023 interview with Peter Attia and separately on his own podcast, Hyman described undergoing biological age testing (epigenetic methylation clocks, telomere length assays) and reporting a result approximately 20 years below his chronological age. He attributes this to a protocol he outlines in Young Forever and in public interviews. That protocol includes:

• A Pegan-style diet (mostly plants, quality animal protein, no ultra-processed food)
• High-intensity interval training plus strength training six days per week
• Seven to nine hours of sleep with tracking devices
• Over 40 daily supplements at various points (he has publicly stated he has since reduced this number)
• Off-label pharmaceutical agents including low-dose rapamycin and, at earlier stages, metformin

He has also discussed hormone optimization including testosterone, DHEA, and thyroid support, framing these as restoring youthful physiologic levels rather than treating disease states. These statements appear across multiple podcast appearances and are sourced directly below where possible.

Why Clinicians Cannot Ignore This

Patients who arrive citing Hyman are not fringe seekers. A 2022 survey published in JAMA Network Open found that 36% of U.S. Adults had used at least one complementary or integrative health approach in the prior 12 months, and interest in longevity-specific interventions rose sharply post-pandemic (1). Ignoring the conversation pushes patients toward unmonitored self-prescribing.

The Diet and Lifestyle Foundation: What the Evidence Actually Shows

Hyman's dietary recommendations have a stronger evidence base than his pharmaceutical ones. That distinction matters when counseling patients.

Caloric Quality, Not Caloric Counting

The Pegan diet Hyman advocates shares principles with both the Mediterranean diet and low-glycemic eating patterns. The PREDIMED trial (N=7,447) showed a Mediterranean diet supplemented with olive oil or nuts reduced major cardiovascular events by approximately 30% compared with a low-fat control diet (2). A 2024 meta-analysis in The Lancet covering 20 cohort studies confirmed that higher ultra-processed food consumption was associated with a 21% increased risk of all-cause mortality (3).

Exercise: The Most Strong Anti-Aging Signal

High-intensity interval training (HIIT) and resistance training, both components of Hyman's stated regimen, carry the strongest longevity data of any single intervention. A 2017 study in Cell Metabolism (N=72) showed that HIIT reversed aging-related declines in mitochondrial function and skeletal muscle protein synthesis (4). VO2 max, which HIIT increases, is the single strongest predictor of all-cause mortality across multiple large cohort studies.

Sleep Optimization

Hyman's emphasis on seven to nine hours of sleep aligns with CDC recommendations and with a 2021 analysis in Nature Communications (N=500,000+) showing that both short sleep (<6 hours) and long sleep (>9 hours) independently predicted earlier mortality, with the nadir of risk between 7 and 8 hours (5).

Supplements Hyman Discusses: Evidence Tier by Tier

Hyman has publicly discussed more than 40 supplements. Clinicians need a quick triage framework. Below, the most commonly cited ones are grouped by evidence quality.

Tier 1: Reasonable Evidence in Humans

Omega-3 fatty acids. The VITAL trial (N=25,871) showed that omega-3 supplementation (1 g/day EPA+DHA) reduced cardiovascular mortality by 20% in participants not consuming fish regularly (6).

Vitamin D. The same VITAL trial showed no significant reduction in cancer incidence but a 17% reduction in cancer mortality with 2,000 IU/day vitamin D3 supplementation in adults followed for 5.3 years. Baseline deficiency matters: patients with 25-OH vitamin D below 20 ng/mL are the most likely to benefit (6).

Magnesium. A 2016 meta-analysis in BMJ Open (N=1 million+, 40 prospective cohorts) found each 100 mg/day increment in magnesium intake was associated with a 22% lower risk of heart failure and a 7% lower risk of stroke (7).

Tier 2: Promising Animal Data, Weak Human Evidence

NAD+ precursors (NMN and NR). Hyman discusses these extensively. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) do raise circulating NAD+ levels in short-term human trials. A 2022 randomized controlled trial of NMN (250 mg/day) in 80 postmenopausal women showed improved muscle insulin sensitivity at 10 weeks (8). This is a single outcome in one population. No long-term mortality or disease-prevention RCT exists in humans. Preclinical data from mouse studies are compelling but do not translate automatically.

Resveratrol. Sirtuin activation in animal models drove enormous enthusiasm. Human RCTs have not replicated meaningful longevity endpoints. A 2014 prospective cohort study in JAMA Internal Medicine (N=783) found no association between urinary resveratrol metabolites and longevity outcomes (9).

Tier 3: Insufficient Human Data for Routine Recommendation

Several compounds Hyman has mentioned, including fisetin, spermidine, and alpha-ketoglutarate, have exciting senolytic or epigenetic mechanisms in cell and animal models. Human clinical trial data are insufficient to make a risk-benefit recommendation in routine practice as of 2025.

HealthRX Clinical Triage Framework for Longevity Supplements: When a patient presents with a supplement list inspired by longevity influencers, evaluate each agent against three criteria: (1) Does at least one adequately powered human RCT show a clinically meaningful endpoint (not just a biomarker)? (2) Does the dose used in that trial match what the patient plans to take? (3) Does the supplement interact with any current medications? Agents failing criterion 1 should be documented as "investigational" in the chart, and patients should be advised they are participating in an uncontrolled self-experiment.

Pharmaceutical Longevity Agents: Rapamycin and Metformin

This is where the clinical risk-benefit conversation becomes most demanding. Hyman has discussed both rapamycin and metformin in the context of longevity, and patients are asking for prescriptions.

Rapamycin: Compelling Preclinical Data, Real Clinical Risks

Rapamycin (sirolimus) inhibits mTORC1, a nutrient-sensing pathway strongly implicated in aging across species. Intermittent low-dose rapamycin (approximately 5 mg weekly) has been adopted by a subset of longevity physicians including those in Hyman's broader network.

The preclinical evidence is striking. Rapamycin extended median lifespan by 9 to 14% in genetically heterogeneous mice, even when started at an equivalent of age 60 in humans (10). The Interventions Testing Program at the National Institute on Aging replicated this finding across three independent sites.

Human data remain limited. Rapamycin is FDA-approved for organ transplant rejection prophylaxis and certain cancers. At transplant doses (2 to 5 mg/day continuous), adverse effects include impaired wound healing, stomatitis, hyperlipidemia, and immunosuppression sufficient to increase infection risk.

Whether intermittent low-dose regimens (1 to 6 mg weekly) confer the longevity benefit with an acceptable safety profile is unknown. The PEARL trial (NCT04488601) is an ongoing RCT examining 5 mg/week rapamycin in healthy adults, but results are not yet published. Prescribing rapamycin off-label for longevity today means accepting that risk-benefit data simply do not exist.

The Endocrine Society's position, and the consensus of most academic longevity researchers, is that off-label rapamycin should not be prescribed outside a clinical trial or a highly specialized practice with close monitoring. Clinicians who receive patient requests should explain this clearly.

Metformin: A Stronger Evidence Story

Metformin has a more developed human longevity case. Beyond its approved indication in type 2 diabetes, observational data suggest metformin users have lower all-cause mortality than matched non-diabetic controls. The TAME (Targeting Aging with Metformin) trial, funded by the American Federation for Aging Research, is a formal multi-site RCT designed to test whether metformin (1,500 mg/day) delays the onset of age-related disease in non-diabetic adults aged 65 to 79. Results are expected around 2026.

The American Diabetes Association (ADA) 2024 Standards of Care note metformin's strong safety profile and low cost but do not endorse it for anti-aging use outside clinical trials (11).

One practical concern: metformin may blunt exercise-induced mitochondrial adaptations. A 2019 RCT in Aging Cell (N=53) found metformin attenuated the increase in mitochondrial respiration normally produced by aerobic exercise training (12). For patients combining metformin with an aggressive exercise protocol like Hyman's, this interaction deserves discussion.

Hormone Optimization: The Most Clinically Nuanced Area

Hyman has been publicly open about using testosterone and DHEA as part of what he frames as restoring youthful hormonal physiology. Patients asking about this often conflate "optimization" with evidence-based treatment of documented deficiency.

Testosterone Therapy

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men states: "We suggest testosterone therapy for men with low testosterone levels and clinical symptoms of androgen deficiency" (13). The guideline explicitly does not support testosterone use to delay normal aging in eugonadal men.

The TRAVERSE trial (N=5,246), published in NEJM in 2023, was the first adequately powered cardiovascular safety RCT of testosterone therapy in men with hypogonadism and elevated cardiovascular risk. Testosterone produced no significant increase in major adverse cardiovascular events versus placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17), but did show a higher rate of pulmonary embolism and atrial fibrillation in the testosterone group (14).

Patients seeking testosterone for biological age reversal, rather than symptomatic hypogonadism, should be counseled that the TRAVERSE data apply to a high-risk symptomatic population. The safety and efficacy data in eugonadal, healthy older men are not established.

DHEA

DHEA is available over the counter in the United States and Hyman has discussed it in the context of adrenal reserve. A 2006 Cochrane review found no consistent benefit of DHEA supplementation on body composition, sexual function, or well-being in aging adults (15). DHEA can convert to estrogen and testosterone peripherally, creating unpredictable hormonal effects, particularly in women with hormone-sensitive conditions.

Thyroid Optimization

Hyman advocates for ensuring free T3 and free T4 are in the "optimal" range rather than simply within the broad laboratory reference range. Some functional medicine practitioners prescribe desiccated thyroid (T4 plus T3) to achieve this. The American Thyroid Association does not recommend treating subclinical hypothyroidism (TSH 4.5 to 10 mU/L) in adults over 65 due to risks including atrial fibrillation and bone loss (16).

Biological Age Testing: Useful Signal or Expensive Noise?

Hyman regularly references epigenetic clocks (Horvath clock, DunedinPACE, GrimAge) as evidence that his interventions are working. These tools measure DNA methylation patterns that correlate with biological aging rate.

GrimAge, developed by Steve Horvath and colleagues, predicts time to death more accurately than chronological age across multiple populations (17). That predictive validity is established. What is not established is whether an individual can meaningfully improve their GrimAge score by taking a specific supplement stack, and whether a change in that score translates into actual mortality reduction.

The Endocrine Society's 2023 scientific statement on aging biomarkers states: "Epigenetic clocks have demonstrated strong population-level associations with aging phenotypes, but their utility as individual clinical decision-making tools requires further prospective validation." Clinicians should convey this distinction to patients who arrive with printed methylation clock results and a supplement purchase receipt.

What Clinicians Should Actually Say in the Room

Patients who admire Dr. Hyman are often highly motivated, health-literate, and capable of engaging with nuance. A dismissive response loses them. A blanket endorsement is irresponsible.

A Practical Conversational Framework

Start by separating the protocol into three tiers during the visit itself:

Tier A (endorse and support): Whole-food diet, resistance training, HIIT, seven to nine hours of sleep, omega-3s, vitamin D if deficient, magnesium if dietary intake is low. These recommendations are concordant with major guidelines and carry meaningful evidence.

Tier B (monitor if already using, discuss risks): Metformin off-label, NMN/NR, DHEA. If the patient is already taking these, document in the chart, check for interactions, and order relevant labs (CBC, CMP, fasting glucose, lipids, hormone panel).

Tier C (require specialist co-management or active clinical trial enrollment): Off-label rapamycin, testosterone without documented hypogonadism, high-dose thyroid hormone without documented hypothyroidism. These should not be initiated in a routine primary care visit without specialist input.

Documenting the Conversation

Use the SOAP note to document the patient's self-directed longevity interventions as current medications and supplements. This protects the patient from dangerous drug interactions and protects the clinician from liability. A patient taking rapamycin who then requires surgery or develops an infection needs their prescribing team to know.

The Broader Clinical Context: Longevity Medicine as a Field

Longevity medicine is moving from fringe to academic mainstream, but the pace varies by intervention. The American College of Lifestyle Medicine and the American Board of Physician Specialties now recognize lifestyle medicine as a formal specialty. The Buck Institute for Research on Aging and the National Institute on Aging are funding increasingly rigorous human trials.

The Karolinska Institutet's 2024 study (N=110,000 Swedish adults followed for 30 years) found that the combination of never smoking, moderate alcohol consumption, regular physical activity, and healthy diet was associated with 12 additional years of disease-free life compared with adults meeting none of those criteria (18). That is a larger effect size than any single pharmaceutical candidate in the longevity pipeline.

Clinicians who engage with longevity medicine need to read the primary literature, not the podcast system. Hyman points toward trials and mechanisms worth knowing. The clinical obligation is to apply the same evidentiary standard to his recommendations as to any other therapeutic claim.

Safety Monitoring for Patients Already on a Hyman-Inspired Protocol

Patients may arrive already deep into a longevity stack. The following labs and monitoring intervals are reasonable for ongoing oversight.

Baseline Labs at First Visit

Order a comprehensive metabolic panel, CBC, fasting insulin, HbA1c, fasting lipids, 25-OH vitamin D, magnesium (RBC, not serum), free and total testosterone (morning draw), DHEA-S, TSH with reflex to free T4 and free T3, and a full thyroid antibody panel if autoimmune thyroid disease is possible. Depending on age and risk profile, add inflammatory markers: hs-CRP and Lp(a).

Monitoring Intervals

Patients on off-label metformin should have HbA1c, CMP, and B12 checked at 6 months and annually. Metformin causes B12 malabsorption in roughly 10 to 30% of long-term users (19).

Patients on testosterone therapy require hematocrit at 3 to 6 months (polycythemia risk), PSA annually if over 40, and symptom review. The Endocrine Society 2018 guideline recommends a testosterone level 3 to 6 months after initiation to confirm therapeutic range (target: 400 to 700 ng/dL mid-cycle) (13).

Patients on off-label rapamycin should have a lipid panel and CBC at 3-month intervals given the known dyslipidemia and thrombocytopenia signals at higher doses. Fasting glucose monitoring is also warranted given rapamycin's known diabetogenic effect via mTORC2 inhibition at higher doses.